Kirsten Kuhn: Delaying plans to expand access to opioid overdose reversal drug could cost lives (Column)
”This commission may consider a delay of a week or two to be no big deal, simply a way of doing their due diligence. But it very well could be the difference between life and death for one of our community members,” Kirsten Kuhn writes in this column.